Page 33 - Future Planet News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Future Planet Capital Buys VC Firm Midven Posted on 04/08/2021 Future Planet Capital Holdings Limited (FPC) purchased Midven Ltd., a U.K. venture capital firm. The deal will enable Future Planet to grow its extensive global innovation network, which includes Berkeley, Cambridge, Harvard, MIT, and Oxford, by combining them with Midven’s access to U.K. Government funded scientific research. Midven, which is supported by investors including the British Business Bank and European Investment Bank, manages the UK Innovation and Science Seed Fund (UKI2S) and the £35 million MEIF West Midlands Gro...

NEXTDC launches 'first of its kind' carbon neutrality program 18 Mar 2021 Australian data centre provider NEXTDC has launched a carbon neutrality program, the likes of which have been called the first of its kind in the local market. The NEXTNeutral data centre program encourages organisations to advance their own sustainability priorities, and to work with NEXTDC with the aim of using carbon offsets to ‘decarbonise the digital economy’. NEXTDC currently operates as a 100% carbon neutral company under the Australian Government’s Climate Active Program, while the NEXTNeutral solutio...

Future Planet Capital: Future Planet Invests in Vaccitech's Series B Financing Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168 million before expenses. Do...

Posted on 7556 Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168 million before expenses. Doug...

Provided by Dow Jones By Jenny Strasburg LONDON -- The Oxford startup behind AstraZeneca PLC's Covid-19 vaccine has raised $168 million in new funding, which it plans to use to adopt its vaccine technology for the treatment of other diseases. The move is a step in Vaccitech Ltd.'s preparations for going public as soon as this year, according to people familiar with the plans. The moves were first reported by The Wall Street Journal. The biotechnology company is raising funds at a time its vaccine work is in the spotlight. It played an early role developing...